PURPOSE To provide evidence-based recommendations for practicing physicians and
other health care providers on immunotherapy and biomarker testing for head and neck …

Recent advances have permitted successful therapeutic targeting of the immune system in
head and neck squamous cell carcinoma (HNSCC). These new immunotherapeutic targets …

Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …

Introduction: The majority of patients with locally advanced head and neck squamous cell
carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M …

Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of
about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Head and neck cancers are a diverse group of malignancies that includes an increasing
number of virally mediated cancers in addition to tumors caused by tobacco and alcohol …

Immunotherapy has revolutionized cancer treatment in the past 2 decades, mostly with
immune checkpoint blockade approaches. In squamous cell carcinoma of the head and …

Background Locoregionally advanced, recurrent, and metastatic squamous cell carcinomas
of the head and neck (SCCHN) remain difficult to treat disease entities, in which systemic …

Relapsed and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a
heterogeneous disease previously associated with poor prognosis and limited treatment …